Osteopontin facilitates tumor metastasis by regulating epithelial–mesenchymal plasticity

Rongjie Jia¹,², Yingchao Liang¹,3,6, Rui Chen¹,6, Guoke Liu¹, Hao Wang¹, Min Tang¹, Xuyu Zhou⁴, Huajing Wang¹, Yang Yang¹, Huafeng Wei², Bohua Li¹, Yipeng Song³ and Jian Zhao*¹

Tumor metastasis leads to high mortality; therefore, understanding the mechanisms that underlie tumor metastasis is crucial. Generally seen as a secretory protein, osteopontin (OPN) is involved in multifarious pathophysiological events. Here, we present a novel pro-metastatic role of OPN during metastatic colonization. Unlike secretory OPN (sOPN), which triggers the epithelial–mesenchymal transition (EMT) to initiate cancer metastasis, intracellular/nuclear OPN (iOPN) induces the mesenchymal–epithelial transition (MET) to facilitate the formation of metastases. Nuclear OPN is found to interact with HIF2α and impact the subsequent AKT1/miR-429/ZEB cascade. In vivo assays confirm that the progression of metastatic colonization is accompanied by the nuclear accumulation of OPN and the MET process. Furthermore, evidence of nuclear OPN in the lung metastases is exhibited in clinical specimens. Finally, VEGF in the microenvironment was shown to induce the translocation of OPN into the nucleus through a KDR/PLCγ/PKC-dependent pathway. Taken together, our results describe the pleiotropic roles of OPN in the tumor metastasis cascade, which indicate its potential as an effective target for both early and advanced tumors.

Received 25.7.16; revised 03.11.16; accepted 10.11.16; Edited by M Agostini

Metastasis is responsible for the majority of cancer-associated deaths. Plasticity of the cellular phenotype is critical for tumor metastasis. Epithelial–mesenchymal transition (EMT) endows epithelial-derived tumor cells with migratory and invasive properties, which facilitates the escape from primary sites in the early stage of metastatic dissemination.¹⁻⁵ Morphological analysis revealed similarities of metastatic lesions and primary tumors.³,⁴ and miR-200s promote distant metastatic colonization by inducing mesenchymal–epithelial transition (MET).⁵ These findings suggest that MET, the reversal of EMT, can convert disseminated mesenchymal tumor cells back to an epithelial state in the later stage of metastatic colonization. Taken together, EMT and MET function in the initiation and termination stage of tumor metastasis, respectively. The crucial role of EMT has been well-recognized, but relatively few studies have focused on the role and mechanism of MET.

Considered to be a canonical secretory protein, the multifunctional role of osteopontin (OPN) has been extensively studied in the past.⁶ High cytoplasmic OPN staining was observed in multiple tumors and the OPN level is closely correlated with the pathological stage.⁷ Blocking OPN in breast cancer cells was reported to decrease the expression of SNAIL, SLUG, and TWIST, which suggests that secretory OPN (sOPN) is critical in EMT and tumor metastasis.⁸ However, knockout phenotypes cannot be fully rectified by treatment of the OPN-knockout mice or cells with recombinant OPN, and antibody neutralization of OPN in the wild-type mice or cells did not reproduce knockout phenotypes.⁹ In our previous work, recombinant human OPN (rhOPN) did not fully compensate for the weakened metastatic ability of HCC cells by OPN interference.¹⁰ Researchers gradually recognized that intracellular OPN (iOPN) existed and functioned separately from sOPN. Since the first introduction,¹¹ three types of iOPN have been discovered: perimembranous,¹² nuclear,¹³ and cytoplasmic.¹⁴ All these studies suggest that iOPN may have important roles in various cytoplasmic behaviors. However, the role of iOPN in cancer progression remains largely elusive.

Here, we investigated the pro-metastatic mechanism of OPN from a brand-new perspective. In accord with previous studies,¹⁵,¹⁶ sOPN induced EMT in cancer; whereas the nuclear OPN triggered MET through the AKT1/miR-429/ZEB axis through interaction with HIF2α. In vivo studies and patient samples further supported the diverse roles of sOPN and iOPN in tumor metastasis.

Results

Expression of OPN in cancer cells. Long regarded as a canonical secretory protein, OPN was recently identified to function intracellularly. The secretory form of OPN (sOPN), localized in the Golgi apparatus, contains an N-terminal signal sequence, which allows it to target secretory vesicles and be secreted extracellularly. To analyze the distinct expression of OPN in cancer cells, dual immunofluorescence staining of OPN and Golgi matrix protein 130 (GM130), the
Golgi marker, was performed. Cancer cells can be classified into three types according to the OPN expression (Figure 1a). Type I cells contain only sOPN, such as HepG2 and NCI-H1299. Type II cells contain both secretory and intracellular/nuclear forms of OPN, such as HCCLM3, MHCC97-L, A549, SK-MES-1, and NCI-H460. Type III cells contain only intracellular/nuclear form of OPN (iOPN), such as Hep3B and 293T. Evident nuclear staining of OPN was also observed in the colon cancer cell lines and breast cancer cell lines (Supplementary Figure S1a).

The results of ELISA assays were consistent with the above data (Figure 1b; Supplementary Figure S1b). Secreted OPN was detected in the supernatant of type I and type II cells, but not in type III cells, even though OPN was expressed considerably (Figure 1c).

sOPN triggers EMT whereas iOPN induces MET. Consistent with previous reports, the blockage of sOPN by shOPN lentivirus in type I cells HepG2 and NCI-H1299 was able to trigger MET featured by the gain of epithelial markers, such as E-cadherin, and the loss of mesenchymal markers, such as N-cadherin, Vimentin, and α-SMA (Figure 2a). Levels of EMT-related transcription factors were greatly decreased (Supplementary Figure S2a). Immunofluorescence showed enhanced membranous staining of E-cadherin and reduced Vimentin staining in OPN-silenced or antibody-neutralized HepG2 or NCI-H1299 cells (Figures 2b and c). Furthermore, OPN silencing induced the gain of E-cadherin or loss of Vimentin, which was reversed when HepG2 or NCI-H1299 cells were exposed to the rhOPN or conditioned media (CM) (Figure 2d). Thus, sOPN was able to trigger EMT.

Interestingly, when OPN was down-regulated in type III and type II cells Hep3B, HCCLM3, and A549, E-cadherin was decreased, whereas N-cadherin, Vimentin, and α-SMA, as well as EMT-related transcription factors ZEB1 and ZEB2 were increased (Figure 2e; Supplementary Figure S2b). The reduced membranous staining of E-cadherin and increased Vimentin staining were observed in OPN-silenced Hep3B and A549 cells (Figure 2f). In addition, lentivirus encoding iOPN cDNA was employed to overexpress iOPN in Hep3B cells, which had relatively low level of OPN. The enforced expression of iOPN in Hep3B led to increase of E-cadherin and decrease of Vimentin, N-cadherin, and α-SMA, and the EMT-activating transcription factors decreased as well (Figure 2g; Supplementary Figure S2c). The restoration of E-cadherin and loss of Vimentin were also observed, and the over-expressed iOPN was located in the nucleus (Figure 2h). Thus, iOPN may induce MET via ZEB1 and ZEB2.

These results suggest that sOPN and iOPN have diverse effects on the EMT/MET process in cancer cells.
miR-429 has a crucial role in iOPN-induced MET. Many studies have focused on sOPN and EMT regulation, but little is known about iOPN and MET regulation. The microRNA-200 family (miR-200s), including miR-200a, miR-200b, miR-200c, miR-141, and miR-429, has been reported to promote MET by direct targeting the ZEB/E-cadherin axis. Given that iOPN greatly regulates ZEB1 and ZEB2 expression (Supplementary Figure S2), the expression of miR-200s was examined in Hep3B, HCCLM3, and 293T cells. Alterations of miR-141 and miR-429 could be found in all the groups tested, when OPN was either silenced in Hep3B, HCCLM3, and 293T cells (Figure 3a) or over-expressed in Hep3B and 293T cells (Figure 3b). The upregulation of miR-141 and miR-429 was accompanied by the increase of iOPN and vice versa. miR-141/miR-429 mimics was further transfected with OPN knockdown, or

Figure 2  sOPN triggers EMT, whereas iOPN induces MET. (a, e and g) Immunoblot analysis of epithelial marker (E-cadherin) and mesenchymal markers (Vimentin, N-cadherin, and α-SMA) in HepG2, NCI-H1299, Hep3B, HCCLM3, and A549 cells transfected with the indicated lentivirus. (b, f and h) Immunofluorescence staining of E-cadherin and Vimentin in HepG2 and NCI-H1299 cells transfected with denoted lentivirus. Scale bars, 10 μm. (c) Immunofluorescence staining of E-cadherin and Vimentin in HepG2 and NCI-H1299 cells, which were pretreated with control IgG or anti-OPN Ab (at 40 μg/ml). (d) Staining of E-cadherin and Vimentin in HepG2 and NCI-H1299 cells, which were first transfected with the indicated lentivirus and then exposed to rhOPN (40 ng/ml) or conditioned medium (CM). Scale bars, 10 μm.
miR-429 inhibitor with nuclear OPN overexpression in Hep3B cells. miR-429 mimics was found to reverse the decrease of E-cadherin and increase of Vimentin caused by OPN deficiency, whereas miR-429 inhibitors reversed the increase of E-cadherin and decrease of Vimentin induced by nuclear OPN overexpression (Figures 3c and d). In addition, miR-429 mimics attenuated the increase of ZEB1 and ZEB2 expression induced by OPN deficiency, and miR-429 inhibitor reversed the decrease of ZEB1 and ZEB2 expression caused by enforced iOPN expression (Figure 3e). However, treatment with miR-141 mimics or inhibitor was unable to achieve the similar results (Supplementary Figure S3). Taken together, miR-429 has a crucial role in iOPN-induced MET.

iOPN induces miR-429 expression by regulating AKT1 expression. The close relationship between OPN and AKT has been extensively investigated. Generally, OPN activates AKT by the phosphorylation at serine-473.\textsuperscript{20,21} Moreover, AKT1 and AKT2 have been reported to have different roles in regulating miR-200s and EMT. Lower abundance of miR-200s was observed in AKT1-knockout mammary adenocarcinomas than in wild-type or AKT2-knockout ones,\textsuperscript{22} and downregulation of AKT1 rather than AKT2 in IGF-1R-stimulated cells could induce EMT.\textsuperscript{23} We therefore detected AKT1 and AKT2 expression with altered expression of OPN. The expression of AKT1 declined in OPN-deficient group or increased in nuclear OPN-enforced group (Figure 4a). However, alterations of the AKT2 level were less...
obvious. Moreover, the level of phosphorylated AKT1 barely changed (Figure 4b). Thus, different from sOPN, iOPN may regulate the expression level of AKT1 rather than its phosphorylation. Then, siAKT1 and siAKT2 were used in iOPN-overexpressed Hep3B cells to determine the role of AKT1 and AKT2 in iOPN-induced MET. Blocking AKT1 reversed the increase of E-cadherin and decrease of Vimentin evoked by nuclear OPN, whereas AKT2 blockage failed to achieve this effect (Figures 4c and d). Moreover, iOPN-induced upregulation of miR-429 was diminished when AKT1 was knocked down (Figure 4e). These data suggest that iOPN may upregulate AKT1 and miR-429 expression.

**iOPN regulates AKT1 expression by interacting with HIF2α.** The mechanism by which iOPN regulates AKT1 expression was then explored. In the promoter region of AKT1, we found three hypoxia-responsive elements (HREs), GGGCGTGG, GTACGTGG, and AGGCGTGC, located at nt-1444, nt-482, and nt+306, respectively. In a study using the yeast two-hybrid screen analysis, OPN was shown to interact with various proteins, including EPAS1 (HIF2α). Accordingly, we boldly hypothesized that iOPN may combine with HIF2α and regulate AKT1 transcription. Indeed, HIF2α was found to act as a negative regulator of AKT1 at both protein and mRNA level (Figure 5a). To investigate how HIF2α affects AKT1 expression, various truncated mutants of the AKT1 promoter were constructed based on HREs. Transcriptional activities were measured in Hep3B cells, and HIF2α might target nt-93 to nt+410 cis-regulatory elements to repress AKT1 transcription (Figure 5b). Moreover, ectopic iOPN expression could increase the activity of AKT1 promoter and partially reverse HIF2α’s inhibition of AKT1 transcription (Figure 5c). We next sought to determine whether the binding of HIF2α to AKT1 promoter was enhanced in OPN-deficient cells or decreased in iOPN-overexpressed cells (Figure 5d). Thus, iOPN negatively regulates the binding of HIF2α to AKT1 promoter.

The interaction between iOPN and HIF2α was then investigated. Immunofluorescence staining showed co-localization of OPN and HIF2α in the nuclei of 293T, Hep3B and HCCLM3 cells (Figure 5e). In addition, endogenous iOPN and HIF2α could be co-immunoprecipitated in these cell lines (Figure 5f). Further Co-IP assays confirmed the interaction between nuclear OPN and HIF2α (Figure 5g).

Taken together, the interaction of iOPN with HIF2α in the nucleus could negatively regulate the binding of HIF2α to AKT1 promoter and decrease the inhibitory effect of HIF2α on AKT1 transcription, resulting in the upregulation of AKT1 and miR-429.

**OPN deficiency impairs MET and metastatic colonization in the distant organ.** MET occurs in the late phase of distant metastasis. Several studies have demonstrated the restoration of epithelial properties of tumor cells in metastases. Morphological analysis showed cells in the metastatic nidus were round, cuboidal and closely arranged, whereas in corresponding primary tumor foci, cells were spindle-shaped and mesenchymal-like (Figure 6a). Immunohistochemical (IHC) staining showed that E-cadherin, a pivotal hallmark of epithelial status, appeared in the membrane in lung metastases, whereas no obvious E-cadherin expression was detected in primary tumor cells; and OPN expression was increased in the nucleus of metastases (Figure 6b). In addition, cells acquired from resected primary and metastatic nodules were cultured in vitro and subjected to immunofluorescence staining. Consistent with IHC staining, the expressions of membranous E-cadherin and nuclear OPN were significantly higher in cells from lung metastases (Figure 6c). In addition, plate colony-forming assay showed the OPN-decreased group formed fewer tumor colonies, suggesting lung colonization relied on iOPN expression (Figure 6d).
These results suggested the establishment of MET agreed with the dramatic increase of nuclear OPN during metastatic colonization in distant organs.

Moreover, miR-429 expression was higher in metastatic colonies or lung-metastatic HCCLM3 cells (Supplementary Figures S4a and b), which were both in keeping with above data. The overexpression of miR-200s promoted metastatic colonization partly through the direct inhibition of Sec23a expression, which reduces the secretion of metastasis-related proteins, including OPN. miR-429 was found to decrease the expression of Sec23a but not OPN (Supplementary Figure S4c). Mass spectrometry analysis and immunoblotting of CM from Sec23a-silenced HCCLM3 cells showed a global reduction of OPN secretion (Supplementary Figures S4d and e). And immunofluorescence staining showed that OPN was detained intracellularly due to the reduced secretion caused by Sec23a silencing (Supplementary Figure S4f). These data suggest that the nuclear accumulation of OPN in lung metastases resulted in the upregulation of miR-429 and the subsequent suppression of Sec23a expression and OPN secretion, which orchestrated the MET process induced by nuclear OPN.

To verify the impact of OPN on MET and metastasis, we constructed a metastatic model and detected lung metastases via the bioluminescence imaging system. The signal intensity of lung metastases in the shOPN group was remarkably weaker (Figure 6e). In addition, H&E and IHC staining showed that OPN deficiency led to fewer metastases and diminished membranous E-cadherin (Figures 6f and g). These results suggested that iOPN expression is related to MET, which contributes to metastatic colonization in the distant organ.

Furthermore, we analyzed OPN and E-cadherin expression in clinical specimens. In primary tumors of 158 HCC patients, strong cytoplasmic OPN staining and weak E-cadherin expression was observed in most cases (Figure 6h, case 1); in other cases, the low cytoplasmic expression of OPN was accompanied by the membranous location of E-cadherin (Figure 6h, case 2). OPN is closely and negatively correlated with membranous E-cadherin expression according to the statistics in primary tumor lesions of HCC patients (Supplementary Table). As surgical treatment is not advocated once distant metastasis is detected in HCC patients, limited metastatic samples were obtained. In metastatic foci of eight independent HCC patients, the nuclear OPN was accompanied by membranous E-cadherin in five cases (Figure 6h).
This phenomenon strongly suggested that nuclear OPN and epithelial status is closely related in metastases.

VEGF in the microenvironment elicits OPN nuclear accumulation. On the basis of the above observations, the mechanism by which OPN enters the nucleus in metastases aroused our interest. A receptive microenvironment at the destination site is pivotal for the engraftment of disseminated tumor cells. In response to some soluble factors, tumor-associated cells, such as hematopoietic progenitors, initiate the ‘premetastatic niche’ by collaborating with other cell types, such as stromal cells. This establishes a premetastatic microenvironment containing cytokines and matrix-degrading enzymes. We subcutaneously injected HCCLM3 cells and harvested lung tissues on the 1st, 15th, 30th, and 45th day. The harvested lung tissues were homogenized and subjected to cytokine detection. Among all the cytokines detected, densitometry values of Leptin, FGFα, and VEGF increased obviously over time, especially between the 1st and 45th day (Figure 7a; Supplementary Figure S5).

Dual immunofluorescence staining of HCCLM3 cells stimulated with Leptin, FGFα, or VEGF showed that neither Leptin nor FGFα enabled OPN to accumulate in nuclei, whereas interestingly, in cells stimulated by VEGF, obvious accumulation of OPN in nuclei was observed (Figure 7b). In addition, IHC staining showed that VEGF was distributed in the stroma...
surrounding tumor cells with the nuclear accumulation of OPN (Figure 7c). To further validate the impact of VEGF in vivo, an animal model was established as shown in Figure 7d, and bioluminescence imaging assay showed the injection of VEGF antibody impeded lung metastasis. These data highlighted the important role of VEGF in the induction of OPN nuclear accumulation and distant metastasis.

We next tried to explore the mechanism how OPN in metastatic tumor cells translocated to nuclei. Protein shuttling between the nucleus and cytoplasm influences cell function; and posttranslational modifications, especially phosphorylation and acetylation, critically regulate the subcellular localization of intracellular proteins.28,29 We used prediction servers (http://www.cbs.dtu.dk/services/NetPhos and http://www.cbs.dtu.dk/services/NetAcet) to predict the modifications of OPN and found that only phosphorylation (notably phosphoserine) may occur. The immunoprecipitation assay was then performed with anti-OPN antibody followed by immunoblot analysis with anti-phosphoserine antibody. After HCCLM3 cells were stimulated by VEGF, OPN was of more phosphoserine (Figure 7e), suggesting that phosphorylation was associated with the nuclear translocation of OPN. Next the NetPhosK 1.0 server (http://www.cbs.dtu.dk/services/NetPhosK) was used to identify kinases that potentially induced phosphorylation of OPN. Integrating the PTM/Processing information of OPN obtained from the UniProt database, we
identified PKC as the candidate. Thereafter, kinase inhibitor studies showed decreased nuclear distribution of OPN in cells treated with inhibitors of tamoxifen, sotrastaurin, or myricetin, which confirmed the involvement of PKC (Figure 7f).

The binding of VEGF to its receptors induces receptor dimerization and autophosphorylation, leading to the activation of several downstream molecules, including phospholipase Cγ (PLCγ), protein kinase C (PKC), and phosphatidylinositol 3-kinase (PI3K). Several studies have reported the VEGFR2 (KDR)/PLCγ/PKC pathway-mediated VEGF signaling. We then performed antibody neutralization and kinase inhibitor studies, and immunofluorescence staining showed the treatment of KDR antibody or PLCγ inhibitor blocked the nuclear translocation of OPN (Figures 7g and h). All these findings suggested that VEGF induced the phosphorylation and nuclear import of OPN through the KDR/PLCγ/PKC-dependent pathway.

Discussion

In this study, we investigated the expression of OPN in various cancer cells, and found not only sOPN but also iOPN. We then found that sOPN triggers EMT in primary sites, whereas iOPN induces MET in distant metastases. iOPN induces MET through the AKT1/miR-429/ZEB cascade following the combination with HIF2α in nuclei. We further found that VEGF is responsible for the nuclear accumulation of OPN in lung metastases through KDR/PLCγ/PKC-dependent pathway. Our findings support the distinct roles of secretory and iOPN in phenotypic plasticity during different stages of tumor metastases. sOPN promoted EMT to initiate early metastatic dissemination, whereas iOPN evoked MET to facilitate metastatic colonization in the late stage of metastatic colonization.

In 1997, iOPN was initially found in rat calvarial cells by Sodek’s group. They performed the single cell analysis and found two patterns of OPN staining: perinuclear and perinuclear distribution. The perinuclear OPN co-localizing with the Golgi apparatus was the typical sOPN, and iOPN showed perinuclear distribution. Later, the cytoplasmic and nuclear distribution of iOPN was demonstrated. The intracellular immunostaining of OPN show four distinct patterns: perinuclear staining, nuclear retention, cytoplasmic distribution, and perinuclear staining which represents sOPN. Cumulative research has revealed crucial roles of iOPN, including migration, cell cycle, and motility. However, research on the role of iOPN in cancer metastasis is still inconclusive.

Early in the metastatic cascade, cancer cells from the primary tumor undergo EMT, which endows non-invasive tumor cells with the ability to invade and disseminate. In recent years, MET, the reversal of EMT, is believed to contribute to colonization at a secondary site. Versican was found to induce MET of breast cancer cells to favor metastatic development in the lungs. The potent miR-200s promoted MET by directly affecting the ZEB/E-cadherin axis, and high miR-200 expression was required for efficient colonization in secondary organs. The overexpression of miR-429induced MET in metastatic ovarian cancer cells. Despite these findings, functional studies linking MET with metastatic colonization ability are relatively scarce.

AKT, also known as protein kinase B (PKB), is a central node in cell signaling downstream. The AKT family, including AKT1, AKT2, and AKT3, contributes to diverse cellular roles, such as cell survival, growth, proliferation, angiogenesis, and metabolism. AKT signaling has also been implicated in a variety of human cancers. Although three AKT isoforms are structurally homologous and share similar mechanisms of activation, they possess distinct features. AKT1 and AKT2 are extensively expressed, whereas AKT3 has a much more limited distribution. AKT1 and AKT2 have distinct roles in regulating EMT, and the ablation of AKT1 was correlated with the decreased abundance of miR-200s and the subsequent increase of ZEB and suppression of E-cadherin. OPN usually activates AKT by the phosphorylation via kinase like ILK and PI3K. In our study, nuclear OPN was found to regulate the level of AKT1 expression rather than the phosphorylation of AKT1. We demonstrated the negative regulation of HIF2α on AKT1 by ChIP assays and the combination of OPN and HIF2α by Co-IP assays. In conclusion, nuclear OPN can interact with HIF2α and impact the subsequent AKT1/miR-429/ZEB cascade.

The ‘seed and soil’ hypothesis put forward by Steven Paget is a milestone in the study of cancer metastasis. It presents the notion that a conducive microenvironment is essential for malignant cells to engraft distant tissues and form metastases. The ideas that specific organs are predisposed to metastases in certain cancers and that signaling between cytokines, chemokines, and their receptors regulates tumor cell homing to secondary organs are now well established. Recent research has demonstrated that the primary tumor itself is able to improve the microenvironment of secondary organs, termed ‘pre-metastatic niches’, before the arrival of tumor cells. The pre-metastatic niche was first described by Kaplan et al. In response to tumor-derived VEGF and PIGF, bone marrow-derived haematopoietic progenitor cells (HPCs) expressing VEGFR1 home to tumor-specific pre-metastatic sites and form cellular clusters in secondary organs. Clusters of VEGFR1+ HPCs expressing VLA-4, the fibronectin receptor, interact with resident fibroblasts to stimulate fibroblastin production and secrete MMP9 to create fitting niches for the recruitment of disseminating CXCR4+ tumor cells. Subsequent studies have identified other factors and bone marrow-derived cells important in the formation of pre-metastatic niche.

Canonical sOPN is widely recognized to be strongly associated with tumor metastasis, but the role of iOPN has not been fully elucidated. Therefore, a better understanding of the different types of OPN functioning in regulating tumor metastasis is of great importance to craft a more efficient treatment strategy.

Materials and Methods

Cell culture. Human liver cancer cells (Hep3B and HepG2), human lung cancer cells (A549, SK-MES-1, NCI-H460, and NCI-H1299), and the transformed embryonic kidney cell line 293T were purchased from American Tissue Culture
Collection (ATCC, Manassas, VA, USA). HCCLM3 and MHCC97-L were obtained from the Liver Cancer Institute, Zhongshan Hospital, Fudan University (Shanghai, China). Further detail was described in Supplementary Materials and Methods.

Constructs. Lentiviral particles of short hairpin RNA (shRNA) were used to knockdown OPN. Lentiviral vectors encoding the intracellular form of human OPN (iOPN) were generated by using pLenti6/V5-TOPO system (Invitrogen, Carlsbad, CA, USA) and were designated as LV-OPN. The iOPN cDNA was generated from full-length OPN cDNA by deleting the codons from 1 to 15. The empty vector was used as a negative control and was designated as LV-Non. Further details about shRNA and siRNA sequences, plasmids and cell infection are available in Supplementary Materials and Methods.

ELISA. Cells were grown to 90% confluence, and culture media was harvested and subjected to the ELISA kit (QuantiKine assay; R&D, Minneapolis, MN, USA) to detect OPN concentration.

Quantitative real-time PCR. For mRNA analysis, total RNA was isolated using EASYspin Plus tissue/cell RNA extraction kit (RN26; Aidlab, Beijing, China). First-strand synthesis was performed with the PrimerScript RT reagent kit (RR037A; Takara, Dalian, China). Oligo(dT) primers were reverse transcribed (ABI). Mature miRNAs and siRNAs were reverse transcribed (ABI), and qPCR was performed using TaqMan mRNA assays (ABI). U6 values were used to normalize miRNA expression. The list of primers used is provided in Supplementary Table S3.

Immunoblotting, Co-IP analysis, and immunofluorescence staining. Immunoblotting, Co-IP analysis, and immunofluorescence staining were performed as described in Supplementary Materials and Methods. The primary and secondary antibodies are listed in Supplementary Table S4.

Luciferase reporter assays. Luciferase activity was measured as described in Supplementary Materials and Methods.

ChIP assay. Four days after Hep3B cells were transfected with the indicated lentivirus, about 3×10^6 cells were harvested and subjected to the ChIP assay according to the manufacturer’s instructions (Millipore, Billerica, MA, USA). The samples were incubated with the anti-HIF2α antibody (6 μg; Abcam, Cambridge, MA, USA) overnight at 4 °C. PCR was performed for 35 cycles with the annealing temperature at 55 °C. The amplification products were analyzed by electrophoresis with 1.5% agarose gels. The primers used are listed in the Supplementary Table S5.

Animal studies. Animal care and experimental procedures were approved by Shanghai Medical Experimental Animal Care Commission. Male athymic BALB/c nude mice (4–6 weeks old) were purchased from Shanghai Experimental Animal Center of Chinese Academy of Sciences and maintained in specific pathogen-free conditions. Detailed experimental procedures were described in Supplementary Materials and Methods.

HCC samples, histology and IHC. Human HCC primary tumor slides were obtained from Guangxi Cancer Hospital (Nanning, Guangxi, China). Human HCC metastatic tumor slides were provided by Shanghai Xinchao Biotechnology (Shanghai, China). Informed consents were obtained, and the procedure was approved by the hospital ethical committee. Hematoxylin and eosin and IHC were carried out routinely and the detailed protocol was described in Supplementary Materials and Methods.

Plate colony-forming assay and cytokine detection assay. Plate colony-forming assay and cytokine detection assay were performed as described in Supplementary Materials and Methods.

Statistical analysis. Results are presented as mean ± S.D. Quantitative variables were analyzed by the two-tailed Student’s t-test and the Wilcoxon-rank sum test. Statistical significance was set at two-sided P<0.05.

Conflict of Interest

The authors declare no conflict of interest.

Acknowledgements. This work is supported by grants from Ministry of Science and Technology of the People’s Republic of China (2010CB945600 and 2014AA020704), National Natural Science Foundation of China (NSFC) (81030042, 81472719, 81402424, and 31171349), State Key Project for Infected Disease and New Drug Development, Shanghai Key Laboratory of Cell Engineering (14DZ2272300), and Shanghai Leading Academic Discipline Project (B905).

1. Thiery JP. Epithelial–mesenchymal transitions in tumour progression. Nat Rev Cancer 2002; 2: 442–454.
2. Thiery JP, Acloque H, Huang FY, Nieto MA. Epithelial–mesenchymal transitions in development and disease. Cell 2009; 139: 871–890.
3. Chaffer CL, Thompson EW, Williams ED. Mesenchymal to epithelial transition in development and disease. Cels Tissue Organs 2007; 185: 7–19.
4. Gunasinghe NP, Wells A, Thompson EW, Hugo HJ. Mesenchymal–epithelial transition (MET) as a mechanism for metastatic colonisation in breast cancer. Cancer Metastasis Rev 2012; 31: 469–478.
5. Kostal M, El BJ, Buha FM, Ibrahim T, Blanco MA, Cela-Tenasa T et al. Direct targeting of Sec23a by miR-200s influences cancer cell secretary and promotes metastatic colonization. Nat Med 2011; 17: 1101–1108.
6. Rangaswami H, Bulbulie A, Kundu GC. Osteopontin: role in cell signaling and cancer progression. Trends Cell Bio 2006; 16: 78–97.
7. Cappola D, Szabo M, Boulware D, Muraca P, Alaaraj M, Chambers AF et al. Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies. Clin Cancer Res 2004; 10: 184–190.
8. Li NY, Weber CE, Mi Z, Wai PY, Cuevas BD, Kuo PC. Osteopontin up-regulates critical epithelial–mesenchymal transition transcription factors to induce an aggressive breast cancer phenotype. J Am Coll Surg 2013; 217: 17–26.
9. Inoue M, Shinohara ML, Intracellular osteopontin (iOPN) and immunity. Immuno Res 2011; 49: 165–172.
10. Zhao J, Dong L, Liu B, Wu GB, Xu DM, Chen JJ et al. Down-regulation of osteopontin suppresses growth and metastasis of hepatocellular carcinoma via induction of apoptosis. Gastroenterology 2008; 135: 956–968.
11. Zohar R, Lee W, Arora P, Cheifetz S, McCulloch C, Sodeik B. Single cell analysis of osteopontin in osteogenic cultures of fetal rat calvarial cells. J Cell Physiol 1997; 170: 88–100.
12. Zohar R, Suzuki N, Suzuki K, Arora P, Glogauer M, McCulloch CA et al. Intracellular osteopontin is an integral component of the CD44-ERM complex involved in cell migration. J Cell Physiol 2000; 184: 116–130.
13. Zhu B, Suzuki K, Goldberg HA, Ritting SR, Denhardt DT, McCulloch CA et al. Osteopontin modulates CD44-dependent chemotaxis of peritoneal macrophages through G-protein-coupled receptors: evidence of a role for an intracellular form of osteopontin. J Cell Physiol 2004; 198: 155–167.
14. Junaid A, Moon MC, Harding GE, Zahradka P. Osteopontin localizes to the nucleus of 293 cells and associates with p30-like kinase-1. Am J Physiol Cell Physiol 2007; 292: C919–C926.
15. Shinohara ML, Kim HJ, Kim JH, Garcia VA, Cantor H. Alternative translation of osteopontin generates intracellular and secreted isoforms that mediate distinct biological activities in dendritic cells. Proc Natl Acad Sci USA 2008; 105: 7235–7239.
16. Liu Y, Cao L, Chen R, Zhou X, Fan X, Liang Y et al. Osteopontin promotes hepatic progenitor cell expansion and tumorgenicity via activation of beta-catenin in mice. Stem cells 2013; 31: 3589–3590.
17. Igual J, McRae S, Banahuda K, Mai T, Waris G. Mechanism of hepatitis C virus (HCV)-induced osteopontin and its role in epithelial to mesenchymal transition of hepatocytes. J Biol Chem 2013; 288: 36994–37009.
18. Burk U, Schubert J, Weilner U, Schmalhofer O, Vincan E, Spaderna S et al. A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells. EMBO Rep 2008; 9: 582–588.
19. Gregory PA, Ben AG, Paterson EL, Barry SC, Tsokos A, Farshid G et al. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol 2008; 10: 593–601.
20. Dai J, Peng L, Fan K, Wang H, Wei R, Ji G et al. Osteopontin induces angiogenesis through activation of PISK/STATK and ERK1/2 in endothelial cells. Oncogene 2009; 28: 3412–3422.
21. Robertson SW, Ghebali MA. Osteopontin induces beta-catenin signaling through activation of Akt in prostate cancer cells. Exp Cell Res 2010; 316: 1–11.
22. Ippolitos D, Polytarchou C, Hatziapostolou M, Kotakis F, Maroulakou IG, Struhl K et al. MicroRNAs differentially regulated by Akt isoforms control EMT and stem cell renewal in cancer cells. Sci Signal 2009; 2: ra2.
23. Irie HY, Pearsall RV, Grueneberg D, Hiai M, Ravichandran P, Kohtani N et al. Direct roles of Akt and Akt2 in regulating cell migration and epithelial-mesenchymal transition. J Cell Biol 2005; 171: 1023–1034.
24. Long P, Sammakay P, Jenner P, Rose S. A yeast two-hybrid screen reveals that osteopontin associates with MAP1A and MAP1B in addition to other proteins linked to microtubule stability, apoptosis and protein degradation in the human brain. *Eur J Neurosci* 2012; 36: 2733–2742.

25. Psaila B, Lyden D. The metastatic niche: adapting the foreign soil. *Nat Rev Cancer* 2009; 9: 285–293.

26. Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. *Nat Med* 2013; 19: 1423–1437.

27. Seneviratne J, Smyth MJ, Moller A. The pre-metastatic niche: finding common ground. *Cancer Metastasis Rev* 2013; 32: 449–464.

28. Kang HJ, Lee H, Choi HJ, Yoon JH, Shin JS, Ahn YH et al. Non-histone nuclear factor HMGB1 is phosphorylated and secreted in colon cancers. *Lab Invest* 2009; 89: 948–959.

29. Lu B, Antoine DJ, Kwan K, Lundback P, Wahamaa H, Schierbeck H et al. JAK/STAT1 signaling promotes HMGB1 hyperacetylation and nuclear translocation. *Proc Natl Acad Sci USA* 2014; 111: 3568–3573.

30. Sakurai Y, Ohgimoto K, Kataoka Y, Yoshida N, Shibuya M. Essential role of Fik-1 (VEGF receptor 2) tyrosine residue 1173 in vasculogenesis in mice. *Proc Natl Acad Sci USA* 2005; 102: 1076–1081.

31. Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L. VEGF receptor signalling—in control of vascular function. *Nat Rev Mol Cell Biol* 2006; 7: 359–371.

32. Ha CH, Wang W, Jhun BS, Saam A, Hausser A, Pfizenmaier K et al. Protein kinase D-dependent phosphorylation and nuclear export of histone deacetylase 5 mediates vascular endothelial growth factor-induced gene expression and angiogenesis. *J Biol Chem* 2008; 283: 14590–14599.

33. Gao D, Joshi N, Choi H, Ryu S, Hahn M, Catena R et al. Myeloid progenitor cells in the premetastatic lung promote metastases by inducing mesenchymal to epithelial transition. *Cancer Res* 2012; 72: 1384–1394.

34. Park SM, Gaur AB, Lengyel E, Peter ME. The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. *Genes Dev* 2008; 22: 894–907.

35. Chen J, Wang L, Matyunina LV, Hill CG, McDonald JF. Overexpression of miR-429 induces mesenchymal-epithelial transition (MET) in metastatic ovarian cancer cells. *Gynecol Oncol* 2011; 121: 203–205.

36. Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream. *Cell* 2007; 129: 1261–1274.

37. Kaplan RN, Riba RD, Zacharoulis S, Bramley AH, Vincent L, Costa C et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. *Nature* 2005; 438: 820–827.